Last week, Theradiag, a French company specializing in in vitro diagnostics and theranostics (targeted therapy based on findings in diagnostic tests) announced that it has entered a new partnership agreement with pharmaceutical group Biogaran.
Last week, Theradiag, a French company specializing in in vitro diagnostics and theranostics (targeted therapy based on findings in diagnostic tests) announced that it has entered a new partnership agreement with pharmaceutical group Biogaran.
Biogaran is a French pharmaceutical group that specializes in generics. In 2014, Biogaran Biosimilars was created, and in February the following year, Celltrion’s biosimilar infliximab (marketed in the European Union as Remsima) was launched in France by Biogaran.
Through this agreement, Biogaran will offer its Lisa Tracker monitoring kits throughout France to support the biosimilar, and Theradiag will handle implementation, provide training to laboratories, and provide clinician support concerning drug monitoring.
The Lisa Tracker kits are used to monitor patients taking anti-tumor necrosis factor (anti-TNF) treatments for various chronic inflammatory diseases. The kit allows clinicians to monitor patient’s trough plasma levels of circulating tumor necrosis factor (TNF), anti-TNF drug levels, and levels of anti-drug antibodies. The combination of these measurements allows physicians to better optimize the patient’s treatment.
In November 2017, Theradiag announced a similar partnership with another pharmaceutical company, Biogen, to provide the Lisa Tracker kits to its patients treated with another infliximab biosimilar, Flixabi, in France and other European nations.
“Together with our partnerships with Janssen, MSD, Pfizer, and Biogen, this deal with Biogaran will enable us to supply our Lisa Tracker kits with all the infliximabs in the market and also for other monoclonal antibodies. It’s also very good news for doctors and their patients, as it will facilitate more personalized therapies,” said Michel Finance, Theradiag’s CEO.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.